Research
Hormonal
Leptin repletion to pre-weight-loss levels reverses most physiological adaptations (hypometabolism and hyperphagia) in weight-reduced individuals, proving that low leptin drives these adaptations.
While leptin therapy is not currently a standard commercial treatment for obesity, this research highlights that the biological drive to regain weight is mediated by low leptin levels. This underscores why weight maintenance is so difficult and why future pharmacotherapies targeting these pathways (like GLP-1 agonists which mimic satiety signals) are crucial.
GoodSupportsHIGH confidence
The administration of exogenous leptin in physiological doses restores most of the energy and behavioral physiology to pre-weight-loss status in weight-stable weight-reduced individuals.
Why this rating
Based on controlled human studies with leptin administration.
Source
Describing the Weight‐Reduced State: Physiology, Behavior, and Interventions
Louis J. Aronne et al. · Obesity · 2021
DOI 10.1002/oby.23086
narrative_reviewCited 105×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Maintenance of weight loss is physiologically distinct from active weight loss, characterized by a 'perfect physiological storm' of increased appetite and decreased energy expenditure that actively opposes weight maintenance.Good
- Physical activity is a critical factor in successful long-term weight maintenance, likely by mitigating the increased appetite and decreased energy expenditure associated with the weight-reduced state.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →